Markets
BSE See NSE See 39,592.08
157.14 (0.4%)
collapse Related Readings collapse

Stock pick from the chemicals sector

| 3/8/2012 9:00 PM Thursday

Omkar Specialty Chemicals (OSCL) had tapped the markets in January 2011 to garner funds for its capacity expansion plans and for its working capital requirements. After it tanked heavily on the listing date, the counter is currently available at a 39 per cent discount to its issue price of Rs 98 a share.

At the time of analysing its offer, DSIJ had recommended avoiding the IPO, citing expensive valuations as a major concern. Now, at a PE multiple of 7.7x and with its annualised EPS of Rs 7.92, the counter looks attractively priced.

Our confidence stems from OSCL’s constantly improving financial performance. The company reported a five quarter CQGR of 16 per cent and 17 per cent in its topline and bottomline. Moreover, with the capacity expansion expected to go onstream over the coming financial year, we expect OSCL to carry on with its robust performance, and the share prices to go up and create wealth for its shareholders.

OSCL manufactures organic and inorganic intermediates, ranging from derivatives of molybdenum, selenium and iodine to tartaric acid. Its products find major application in the pharmaceuticals industry, which contributes to around 75 per cent of the total revenues. The chemicals, glass, cosmetics and cattle and poultry feeds industries make up the rest of its revenues.

Coming to the investment rationale, OSCL’s proposed capacity expansion  plans seem to be well on track, as the company has already added capacities of  1950 MTPA against the envisaged capacity addition of 3650 MTPA. It has also recently acquired Urdhwa Chemicals based in Ratnagiri, Maharashtra that has  an installed capacity of 2800 MTPA, which is expected to commence operations from May 2012 onwards. Going forward, the management is eyeing a robust topline growth for FY13, as the remaining capacities go live and the revenues from its new acquisition start pouring in.

With the Indian pharma industry expected to witness a strong traction over the coming years and the user industry (bulk drugs) pegged to grow at a five-year CAGR of 21 per cent (according to CRISIL Research), OSCL would ride the wave ahead smoothly, powered by its diverse portfolio of 105 products, the robust capacity expansion and strong clientele comprising industry leaders like Cipla, Dr Reddy’s, Ranbaxy and others.

The only pitfall is its high dependence on imports for raw material, which constitutes 40-50 per cent of its raw material costs. However, despite the high input costs and the sharp rupee depreciation prevailing over the past year, the company has not only managed to maintain its margins but has also reduced its raw material to sales ratio by 700 bps to 68 per cent in the December 2011 quarter. This signifies that it has constantly been able to pass on the costs to its customers, without hampering the demand for its products.

The company has posted a whopping growth of 66 per cent in its topline to Rs 125.94 crore in the nine month period ended December 2011. Despite the 93 per cent rise in interest costs to Rs 6.22 crore, the bottomline grew by 63 per cent to Rs 11.67 crore during the same period. Moreover, with an interest cover ratio of 3.5x, the company looks comfortable with respect to covering its interest costs.

In conclusion, at a CMP of Rs 59.05 which discounts its FY13E EPS of Rs 13.7 at PE of 4.3x, we recommend a 'buy' on the counter with a price target of Rs 91.

Last 5 Quarters Performance
Particulars11-Dec11-Sep11-Jun11-Mar10-Dec
Sales 44.15 39.24 42.56 31.14 24.51
Other Income 0.73 0.73 0.68 0.4 0.09
Operating Profit 8.78 7.75 8.2 6.14 4.69
Interest 2.57 2.12 1.53 1.62 1.3
Depreciation 1.05 1.04 1 0.54 0.48
Net Profit/Loss 4.03 3.62 4.02 2.97 2.12
EPS (in Rs.) 2.05 1.84 2.05 1.52 1.08

Shareholding Pattern as on 31st Dec 2011
Promoter 59.11
FII 5.9
DII 5.2
Corporate Bodies 12.49
Individual Investors 17.1
Others 0.2
Total 100

 

Find More Articles on: DSIJ Magazine, Low Priced Scrip, Stock Recommendations, Fundamental Picks, Product, Small Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

Ducon Infra partners with Sterling & Wilson to bid for large GFD projects

Apurva Joshi / Article rating: 5.0

Ducon Infratechnologies Limited has entered into a strategic tie-up with Sterling & Wilson Private Limited, a flagship group company of Shapoorji Pallonji Group, to jointly bid large-sized FGD tenders. Ducon is an emerging technology company providing solutions in the industrial, infrastructure and digital space to multiple business segments across varied industries.

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.